Key stats
About Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF
Home page
Inception date
May 21, 2024
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Amplify Investments LLC
Distributor
Foreside Fund Services LLC
THNR focuses on the weight loss industry. The fund tracks an index that invests in companies involved in manufacturing and enabling GLP-1 agonist pharmaceutical businesses. GLP-1 agonists seek to lower blood sugar levels, reduce appetite, and promote fullness, with the ultimate potential for weight loss. Starting with an initial universe of companies from the developed markets, the index selects: 1) drug manufacturers, which are firms with GLP-1 agonist drugs that either have been launched or are currently in Food and Drug Administration (FDA) clinical trials, and 2) enablers, which are companies engaged in the outsourced development and manufacturing, as well as the production and distribution of GLP-1 agonist drugs. Drug manufacturers comprise 70% of the portfolio, while enablers cover the remaining 30%. Holdings within each segment are market cap-weighted, subject to individual security capping. The index reconstitutes and rebalances quarterly.
Related funds
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Top 10 holdings
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
THNR trades at 23.11 USD today, its price has fallen −2.92% in the past 24 hours. Track more dynamics on THNR price chart.
THNR net asset value is 23.10 today — it's risen 1.99% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
THNR assets under management is 3.10 M USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
THNR price has risen by 0.97% over the last month, and its yearly performance shows a −12.13% decrease. See more dynamics on THNR price chart.
NAV returns, another gauge of an ETF dynamics, showed a 5.87% increase in three-month performance and has increased by 2.20% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 5.87% increase in three-month performance and has increased by 2.20% in a year.
THNR fund flows account for 567.15 K USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
THNR invests in stocks. See more details in our Analysis section.
THNR expense ratio is 0.59%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, THNR isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, THNR technical analysis shows the neutral rating and its 1-week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating THNR shows the buy signal. See more of THNR technicals for a more comprehensive analysis.
Today, THNR technical analysis shows the neutral rating and its 1-week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating THNR shows the buy signal. See more of THNR technicals for a more comprehensive analysis.
Yes, THNR pays dividends to its holders with the dividend yield of 0.34%.
THNR trades at a premium (0.05%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
THNR shares are issued by Amplify Holding Co. LLC
THNR follows the VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on May 21, 2024.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.